KR20060057992A - ｐ38-ＤＸ2 및 이의 용도 - Google Patents

ｐ38-ＤＸ2 및 이의 용도 Download PDF

Info

Publication number
KR20060057992A
KR20060057992A KR1020050039073A KR20050039073A KR20060057992A KR 20060057992 A KR20060057992 A KR 20060057992A KR 1020050039073 A KR1020050039073 A KR 1020050039073A KR 20050039073 A KR20050039073 A KR 20050039073A KR 20060057992 A KR20060057992 A KR 20060057992A
Authority
KR
South Korea
Prior art keywords
protein
nucleic acid
lung cancer
mrna
cells
Prior art date
Application number
KR1020050039073A
Other languages
English (en)
Korean (ko)
Inventor
김성훈
Original Assignee
재단법인서울대학교산학협력재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인서울대학교산학협력재단 filed Critical 재단법인서울대학교산학협력재단
Priority to US11/264,725 priority Critical patent/US7459529B2/en
Priority to AT05819055T priority patent/ATE521631T1/de
Priority to JP2007542907A priority patent/JP4718556B2/ja
Priority to CN2005800378029A priority patent/CN101087804B/zh
Priority to EP05819055A priority patent/EP1814909B1/en
Priority to PCT/KR2005/003924 priority patent/WO2006057500A1/en
Priority to KR1020050110946A priority patent/KR100762995B1/ko
Priority to ES05819055T priority patent/ES2371479T3/es
Publication of KR20060057992A publication Critical patent/KR20060057992A/ko
Priority to US12/255,943 priority patent/US8003780B2/en
Priority to US13/011,386 priority patent/US20110117572A1/en
Priority to US13/011,174 priority patent/US8431393B2/en
Priority to US15/074,498 priority patent/US9944713B2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020050039073A 2004-11-24 2005-05-10 ｐ38-ＤＸ2 및 이의 용도 KR20060057992A (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US11/264,725 US7459529B2 (en) 2004-11-24 2005-11-01 AIMP2-DX2 and its uses
PCT/KR2005/003924 WO2006057500A1 (en) 2004-11-24 2005-11-18 Use of aimp2dx2 for the diagnosis and treatment of cancer
JP2007542907A JP4718556B2 (ja) 2004-11-24 2005-11-18 癌の診断と治療のためのａｉｍｐ２ｄｘ２の用途
CN2005800378029A CN101087804B (zh) 2004-11-24 2005-11-18 用于诊断和治疗癌症的aimp2dx2的用途
EP05819055A EP1814909B1 (en) 2004-11-24 2005-11-18 Use of aimp2dx2 for the diagnosis and treatment of cancer
AT05819055T ATE521631T1 (de) 2004-11-24 2005-11-18 Verwendung von aimp2dx2 zur diagnose und behandlung von krebs
KR1020050110946A KR100762995B1 (ko) 2004-11-24 2005-11-18 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
ES05819055T ES2371479T3 (es) 2004-11-24 2005-11-18 Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer.
US12/255,943 US8003780B2 (en) 2004-11-24 2008-10-22 AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US13/011,386 US20110117572A1 (en) 2004-11-24 2011-01-21 Antibody Specific to the AIMP2-DX2
US13/011,174 US8431393B2 (en) 2004-11-24 2011-01-21 AIMP2-DX2 gene and its uses
US15/074,498 US9944713B2 (en) 2004-11-24 2016-03-18 Antibody specific to the AIMP2-DX2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040097164 2004-11-24
KR1020040097164 2004-11-24

Publications (1)

Publication Number Publication Date
KR20060057992A true KR20060057992A (ko) 2006-05-29

Family

ID=37153221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020050039073A KR20060057992A (ko) 2004-11-24 2005-05-10 ｐ38-ＤＸ2 및 이의 용도

Country Status (5)

Country Link
JP (1) JP4718556B2 (ja)
KR (1) KR20060057992A (ja)
CN (1) CN101087804B (ja)
AT (1) ATE521631T1 (ja)
ES (1) ES2371479T3 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011248101B2 (en) * 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
EP2945645B8 (de) * 2013-01-17 2019-10-23 Sylvain Tourel Selektives zelltod-induzierendes binäres enzymsystem
KR102297505B1 (ko) * 2016-03-07 2021-09-01 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
EP3375871A1 (en) * 2017-03-13 2018-09-19 SIT Biotech GmbH Selective cell death-inducing enzyme system
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100575251B1 (ko) * 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2

Also Published As

Publication number Publication date
ES2371479T3 (es) 2012-01-03
JP2008521398A (ja) 2008-06-26
JP4718556B2 (ja) 2011-07-06
ATE521631T1 (de) 2011-09-15
CN101087804A (zh) 2007-12-12
CN101087804B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
KR100762995B1 (ko) 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
JP6196350B2 (ja) 診断および治療のための腫瘍関連細胞表面抗原の同定
JP5167464B2 (ja) 肝細胞癌または結腸直腸癌に関連する遺伝子およびポリペプチド
US7807392B1 (en) Lung disease targets and uses thereof
JP2006526992A (ja) 癌を検出し、癌の進行をモニタリングする方法
JP5847755B2 (ja) 細胞を検出する方法、およびこれに有用な薬剤
KR20060057992A (ko) ｐ38-ＤＸ2 및 이의 용도
EP2452948B1 (en) New tumor marker
KR20070113926A (ko) 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
US9789159B2 (en) Diagnosis and treatment of prostate cancer
US20080020461A1 (en) Kinesin-like proteins and methods of use
JP5354634B2 (ja) ヒトａｂｈ８タンパク質、それをコードする遺伝子、およびこれらの治療的又は診断的用途
CN111440870B (zh) CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用
US6613534B2 (en) MAP-2 as a determinant of metastatic potential
WO2021172315A1 (ja) Ｌａｍｃ２－ｎｒ６ａ１スプライシングバリアント及びその翻訳産物
JP4628674B2 (ja) 診断および治療の方法ならびにそのために有用な作用物質
AU2014203702B2 (en) New tumor marker
JP2005511552A (ja) 乳癌において増幅される推定癌遺伝子であるｉｂｃ−１（浸潤乳癌−１）
WO2007037532A1 (ja) Ｓｒｍｓ遺伝子の治療的又は診断的用途

Legal Events

Date Code Title Description
A201 Request for examination